Canopy Growth/$CGC
1D1W1MYTD1Y5YMAX
Capital at risk
About Canopy Growth
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.
- Ticker
- $CGC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,128
- Headquarters
- Smiths Falls, Canada
- Website
- www.canopygrowth.com
Canopy Growth Metrics
BasicAdvanced
$396M
-
-$0.47
2.41
-
Price and volume
Market cap
$396M
Beta
2.41
52-week high
$2.38
52-week low
$0.84
Average daily volume
3.4M
Financial strength
Current ratio
3.037
Quick ratio
2.274
Long term debt to equity
0.349
Total debt to equity
0.403
Interest coverage (TTM)
-1.20%
Profitability
EBITDA (TTM)
-18.669
Gross margin (TTM)
28.52%
Net profit margin (TTM)
-79.22%
Operating margin (TTM)
-20.72%
Effective tax rate (TTM)
0.17%
Revenue per employee (TTM)
$185,920
Management effectiveness
Return on assets (TTM)
-3.92%
Return on equity (TTM)
-39.51%
Valuation
Price to revenue (TTM)
1.595
Price to book
0.8
Price to tangible book (TTM)
1.02
Price to free cash flow (TTM)
-5.595
Free cash flow yield (TTM)
-17.87%
Free cash flow per share (TTM)
-0.168
Growth
Revenue change (TTM)
6.81%
Earnings per share change (TTM)
-79.38%
3-year revenue growth (CAGR)
-2.55%
10-year revenue growth (CAGR)
32.23%
3-year earnings per share growth (CAGR)
-70.14%
10-year earnings per share growth (CAGR)
-3.69%
What the Analysts think about Canopy Growth
Analyst ratings (Buy, Hold, Sell) for Canopy Growth stock.
Analyst projections of the future price of Canopy Growth stock.
Bulls say / Bears say
Q4 FY2026 revenue rose 8.6% year-over-year to C$71.2 million, driven by robust sales momentum and a narrowing adjusted EBITDA loss to C$6.3 million. (Reuters)
Canada medical cannabis revenue in Q4 FY2026 increased 27% year-over-year, reflecting growth in insured patient counts and expanded product assortment. (Reuters)
Canopy Growth relaunched its Tweed brand in the German medical market with three MTL-developed strains, marking its first international product launch following the MTL acquisition. (Reuters)
Q4 FY2026 net revenue of C$71.245 million missed the IBES consensus estimate of C$74.4 million, suggesting weaker-than-expected demand. (Reuters)
Storz & Bickel revenue fell 14% year-over-year in Q4 FY2026, highlighting softness in the vaporizer devices segment. (Reuters)
An adjusted EBITDA loss of C$6.3 million in Q4 FY2026, despite improvements, underscores the company’s continued struggle to reach profitability. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 23 Aug 2026.
Canopy Growth Financial Performance
Revenues and expenses
Canopy Growth Earnings Performance
Company profitability
Upcoming events
No upcoming events
Canopy Growth News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.